Protein C pathway and antithrombin in thrombosis-related gastrointestinal disorders

Öz

Background and Aims: We aimed to determine the frequency of activated protein C resistance and deficiencies of protein C, protein S and antithrombin in different gastrointestinal diseases (portal vein thrombosis, Budd-Chiari syndrome, liver cirrhosis, inflammatory bowel disease and gastrointestinal malignancies), which related with thrombosis etiologically and/or pathogenetically. Materials and Methods: Protein C, protein S and antithrombin activities were measured by functional methods. Activated protein C resistance was detected by the modified method using factor V-deficient plasma. Results: Protein C deficiency in the cirrhosis, malignancy and secondary portal vein thrombosis groups was significantly higher than in the other groups (p

Anahtar Kelimeler

• Thrombosis, protein C, protein S, antithrombin, activated protein C resistance, portal vein thrombosis, Budd-Chiari syndrome, cirrhosis, inflammatory bowel disease

Trombozla ilişkili gastrointestinal hastalıklarda protein C yolağı ve antitrombin

Öz

Giriş ve Amaç: Etyolojisinde tromboz olan ve/veya doğal seyrinde trombotik komplikasyonlarla sık karşılaşılan gastrointestinal hastalıklarda (portal ven trombozu, Budd-Chiari sendromu, karaciğer sirozu, inflamatuar barsak hastalığı ve gastrointestinal malignite) aktive protein C direnci sıklığı ile protein C, protein S ve antitrombin eksikliklerini araştırmak üzere bu prospektif çalışma planlandı. Gereç ve Yöntem: Hastalardan fonksiyonel yöntemlerle protein C, protein S, antitrombin aktiviteleri ve koagülasyon faktörü V’den yoksun test plazması kullanılarak modifiye yöntemle aktive protein C direnci araştırıldı. Bulgular: Protein C eksikliği siroz, malign ve sekonder portal ven trombozu gruplarında diğer gruplardan daha sıktı (p < 0.05). Primer portal ven trombozu ve Budd-Chiari sendromundaki protein C eksikliği ise kontrolden daha fazlaydı (p < 0.05). Protein S eksikliği Budd-Chiari sendromunda diğer tüm gruplardan istatistiksel önemde fazlaydı. ‹nflamatuar barsak hastalığı, malign ve her iki portal ven trombozu grubunda protein S eksikliği oranı siroz ve kontrolden yüksekdi (p < 0.05). Antitrombin eksikliği sirozda diğer tüm gruplardan daha fazlaydı. Aktive protein C direnci varlığı oranı tüm hasta gruplarında kontrolden istatistiksel önemde fazlalık gösteriyordu (p < 0.05). Budd-Chiari sendromunda aktive protein C direnci bulunma oranı ise diğer tüm gruplardan fazlaydı (p < 0.05). Ayrıca sirozlu ve maligniteli hastalarda tromboz varlığıyla aktive protein C direnci bulunması korelasyon gösteriyordu (p < 0.05). Trombofilik faktörlerden iki veya daha fazlasının birarada bulunması tromboz riskinde belirgin artışa neden olmaktaydı. Sonuç: Protein C, protein S ve antitrombin eksikliklerinin ve özellikle aktive protein C direnci varlığının; Budd-Chiari sendromu ve portal ven trombozu etyolojisinde rol oynayabileceği, sirozlu, inflamatuar barsak hastalıklı ve maligniteli hastalarda tromboz gelişme riskini arttırdığı saptandı.

Anahtar Kelimeler

• Tromboz, protein C, protein S, antitrombin, aktive protein C direnci, portal ven trombozu, Budd-Chiari sendromu, siroz, inflamatuar barsak hastalığı

Kaynakça

1. Harker LA. Disorders of hemostasis and thrombosis: Pathogenesis of thrombosis. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, Eds. Hematology 4thed. New York, McGraw Hill 1991; 1559-69.
2. Handin RI. Bleeding and thrombosis. In: Fauci AS, Braunwald Eeds. Harrison’s Principles of Internal Medicine 14thed. New York, McGraw Hill 1998; 339-45.
3. Florell SR, Rodgers GM. Inherited thrombotic disorders: an update. Am J Hematol 1997; 54: 53-60.
4. Martinelli I, Mannuci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-8.
5. Murin S, Marelich G, Arroliga A, Matthay R. Hereditary thrombop- hilia and venous thromboembolism. Am J Respir Crit Care Med 1998; 158: 1369-73.
6. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor an- ticoagulant response to activated protein C: prediction of a cofac- tor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004- 8.
7. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood co- agulation factor V associated with resistance to activated protein C. Nature 1994 ;369: 64-7.
8. Gürgey A, Mesci L. The prevalence of factor V Leiden (1691G-A) mutation in Turkey. Turk J Pediatr 1997; 39: 313-5.

9. Akar N, Akar E, Dalgın G, et al. Frequency of factor V Leiden (1691G-A) mutation in Turkish population. Thromb Haemost 1997; 78: 1527-8.
10. Özbek U, Tangün Y. Frequency of factor V Leiden in Turkey. Br J Haematol 1997; 97: 504-5.
11. Aboud MR, Ma DDF. A comparison between two activated prote- in C resistance methods as routine diagnostic tests for factor V Lei- den mutation. Br J Haematol 1997; 97: 798-803.
12. Tripodi A, Negri B, Bertina RM, Mannuci PM. Screening for the FV:Q506 mutation-evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost 1997; 77: 436-9.
13. Svensson PJ, Zöller B, Dahlbäck B. Evaluation of original and modi- fied APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 332-5.
14. Parikh S, Shah R, Kapoor P. Portal vein thrombosis. Am J Med 2010; 123: 111-9.
15. Kelly DA, Tuddenham EGD. Haemostatic problems in liver disease. Gut 1986; 27: 339-49.
16. Bick RL, Strauss JF, Frenkel EP. Thrombosis and hemorrhage in on- cology patients. Hematol Oncol Clin North Am 1996; 10: 875-907.
17. Hudson M, Chitolie A, Hutton RA, et al. Thrombotic vascular risk factors in inflammatory bowel disease. Gut 1996; 38: 733-7.
18. Dhillon AP, Anthony A, Sim R, et al. Mucosal capillary thrombi in rectal biopsies. Histopathology 1992; 21: 127-33.
19. Michiels JJ, Hamulyak K. Laboratory diagnosis of hereditary throm- bophilia. Semin Thromb Hemost 1998; 24: 309-20.
20. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
21. Thompson NP, Wakefield AJ, Pounder RE. Inherited disorders of coagulation appear to protect against inflammatory bowel disea- se. Gastroenterology 1995; 108: 1011-5.
22. Folwaczny C, Wiebecke B, Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 1999; 94: 1551-5.
23. Liebman HA, Kashani N, Sutherland D, et al. The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. Gastroenterology 1998; 115: 830-4.
24. Probert CSJ, Haslam N, Alsam S, Standen G. Is factor V Leiden as- sociated with inflammatory bowel disease? Gut 1997; 40 (Suppl1): A36.
25. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25: 173-82.
26. Monreal M, Prandoni P. Venous thromboembolism as first mani- festation of cancer. Semin Thromb Hemost 1999; 25: 131-6.
27. Violi F, Ferro D, Basili S, et al. Ongoing prothrombotic state in the portal circulation of cirrhotic patients. Thromb Haemost 1997; 77: 44-7.
28. Tilanus HW. Budd-Chiari syndrome. Br J Surg 1995; 82: 1023-30.
29. Mohanty D, Shetty S, Narayanan TS, Abraham P. Factor V Leiden mutation and Budd-Chiari syndrome. Blood 1998; 92: 1838-9.
30. Das R, Garewal G, Chawla Y, Dhiman RK. Prevalence of the factor V Leiden mutation in portal and hepatic vein thrombosis. Gut 1998; 43: 147.
31. Mahmoud AEA, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997; 40: 798-800.
32. Chamouard P, Pencreach E, Maloisel F, et al. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroen- terology 1999; 116: 144-8.